|
1
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Matano E, Tagliaferri P, Libroia A,
Damiano V, Fabbrocini A, De Lorenzo S and Bianco AR: Gemcitabine
combined with continuous infusion 5-fluorouracil in advanced and
symptomatic pancreatic cancer: A clinical benefit-oriented phase II
study. Br J Cancer. 82:1772–1775. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xu M, Li L, Liu Z, Jiao Z, Xu P, Kong X,
Huang H and Zhang Y: ABCB2 (TAP1) as the downstream target of SHH
signaling enhances pancreatic ductal adenocarcinoma drug
resistance. Cancer Lett. 333:152–158. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen M, Xue X, Wang F, An Y, Tang D, Xu Y,
Wang H, Yuan Z, Gao W, Wei J, Zhang J and Miao Y: Expression and
promoter methylation analysis of ATP-binding cassette genes in
pancreatic cancer. Oncol Rep. 27:265–269. 2012.PubMed/NCBI
|
|
5
|
Hopper-Borge E, Xu X, Shen T, Shi Z, Chen
ZS and Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a
resistance factor for nucleoside analogues and epothilone B. Cancer
Res. 69:178–184. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Szakacs G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Binkhathlan Z and Lavasanifar A:
P-glycoprotein inhibition as a therapeutic approach for overcoming
multidrug resistance in cancer: Current status and future
perspectives. Curr Cancer Drug Targets. 13:326–346. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Choudhuri S and Klaassen CD: Structure,
function, expression, genomic organization, and single nucleotide
polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP)
efflux transporters. Int J Toxicol. 25:231–259. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gatti L, Beretta GL, Cossa G, Zunino F and
Perego P: ABC transporters as potential targets for modulation of
drug resistance. Mini Rev Med Chem. 9:1102–1112. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hsu MC, Pan MR, Chu PY, Tsai YL, Tsai CH,
Shan YS, Chen LT and Hung WC: Protein arginine methyltransferase 3
enhances chemoresistance in pancreatic cancer by methylating
hnRNPA1 to increase ABCG2 Expression. Cancers (Basel). 11:82018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vesel M, Rapp J, Feller D, Kiss E, Jaromi
L, Meggyes M, Miskei G, Duga B, Smuk G, Laszlo T and Karner I:
ABCB1 and ABCG2 drug transporters are differentially expressed in
non-small cell lung cancers (NSCLC) and expression is modified by
cisplatin treatment via altered Wnt signaling. Respir Res.
18:522017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen B, Zhang D, Kuai J, Cheng M, Fang X
and Li G: Upregulation of miR-199a/b contributes to cisplatin
resistance via Wnt/β-catenin-ABCG2 signaling pathway in
ALDHA1+colorectal cancer stem cells. Tumor Biol.
39:1–14. 2017. View Article : Google Scholar
|
|
13
|
Martins-Neves SR, Paiva-Oliveira DI,
Wijers-Koster PM, Abrunhosa AJ, Fontes-Ribeiro C, Bovée JV,
Cleton-Jansen AM and Gomes CM: Chemotherapy induces stemness in
osteosarcoma cells through activation of Wnt/β-catenin signaling.
Cancer Lett. 370:286–295. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Spee B, Carpino G, Schotanus BA,
Katoonizadeh A, Vander Borght S, Gaudio E and Roskams T:
Characterisation of the liver progenitor cell niche in liver
diseases: Potential involvement of Wnt and Notch signaling. Gut.
59:247–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Peng C, Zhang X, Yu H, Wu D and Zheng J:
Wnt5a as a predictor in poor clinical outcome of patients and a
mediator in chemoresistance of ovarian cancer. Int J Gynecol
Cancer. 21:280–288. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hung TH, Hsu SC, Cheng CY, Choo KB, Tseng
CP, Chen TC, Lan YW, Huang TT, Lai HC, Chen CM and Chong KY: Wnt5a
regulates ABCB1 expression in multidrug-resistant cancer cells
through activation of the non-canonical PKA/β-catenin pathway.
Oncotarget. 5:12273–12290. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cao J and Wang Q, Wu G, Li S and Wang Q:
miR-129-5p inhibits Gemcitabine resistance and promotes cell
apoptosis of bladder cancer cells by targeting Wnt5a. Int Urol
Nephrol. 50:1811–1819. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ying J, Li H, Yu J, Ng KM, Poon FF, Wong
SC, Chan AT, Sung JJ and Tao Q: WNT5A exhibits tumor-suppressive
activity through antagonizing the Wnt/beta-catenin signaling, and
is frequently methylated in colorectal cancer. Clin Cancer Res.
14:55–61. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang Z, Zhou C, Cheng L, Yan B, Chen K,
Chen X, Zong L, Lei J, Duan W, Xu Q, et al: Inhibiting YAP
expression suppresses pancreatic cancer progression by disrupting
tumor-stromal interactions. J Exp Clin Cancer Res. 37:692018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McDermott M, Eustace AJ, Busschots S,
Breen L, Crown J, Clynes M, O'Donovan N and Stordal B: In vitro
development of chemotherapy and targeted therapy drug-resistant
cancer cell lines: A Practical Guide with Case Studies. Front
Oncol. 6:402014.PubMed/NCBI
|
|
21
|
Qiu X, Jiao J, Li Y and Tian T:
Overexpression of FZD7 promotes glioma cell proliferation by
upregulating TAZ. Oncotarget. 7:85987–85999. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liang C, Shi S, Meng Q, Liang D, Ji S,
Zhang B, Qin Y, Xu J, Ni Q and Yu X: Complex roles of the stroma in
the intrinsic resistance to gemcitabine in pancreatic cancer: Where
we are and where we are going. Exp Mol Med. 49:e4062017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Amrutkar M and Gladhaug IP: Pancreatic
Cancer Chemoresistance to Gemcitabine. Cancers (Basel). 9:1572017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Arensman MD, Kovochich AN, Kulikauskas RM,
Lay AR, Yang PT, Li X, Donahue T, Major MB, Moon RT, Chien AJ and
Dawson DW: WNT7B mediates autocrine Wnt/β-catenin signaling and
anchorage-independent growth in pancreatic adenocarcinoma.
Oncogene. 33:899–908. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gordon MD and Nusse R: Wnt signaling:
Multiple pathways, multiple receptors, and multiple transcription
factors. J Biol Chem. 281:22429–22433. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Anastas JN, Kulikauskas RM, Tamir T, Rizos
H, Long GV, von Euw EM, Yang PT, Chen HW, Haydu L, Toroni RA, et
al: WNT5A enhances resistance of melanoma cells to targeted BRAF
inhibitors. J Clin Invest. 124:2877–2890. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Frank NY, Schatton T and Frank MH: The
therapeutic promise of the cancer stem cell concept. J Clin Invest.
120:41–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Todaro M, Francipane MG, Medema JP and
Stassi G: Colon cancer stem cells: Promise of targeted therapy.
Gastroenterology. 138:2151–2162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Crea F, Danesi R and Farrar WL: Cancer
stem cell epigenetics and chemoresistance. Epiqenomics. 1:63–79.
2009. View Article : Google Scholar
|
|
30
|
Wang XQ, Ongkeko WM, Chen L, Yang ZF, Lu
P, Chen KK, Lopez JP, Poon RT and Fan ST: Octamer 4 (Oct4) mediates
chemotherapeutic drug resistance in liver cancer cells through a
potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology.
52:528–539. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Song KH, Choi CH, Lee HJ, Oh SJ, Woo SR,
Hong SO, Noh KH, Cho H, Chung EJ, Kim JH, et al: HDAC1 upregulation
by NANOG promotes multidrug resistance and a stem-like phenotype in
immune edited tumor cells. Cancer Res. 77:5039–5053. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jiang H, Xiong W, Chen L, Lv Z, Yang C and
Li Y: Knockdown of the long noncoding RNA HOTTIP inhibits cell
proliferation and enhances cell sensitivity to cisplatin by
suppressing the Wnt/β-catenin pathway in prostate cancer. J Cell
Biochem. 120:8965–8974. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
An Y and Ongkeko WM: ABCG2: The key to
chemoresistance in cancer stem cells? Expert Opin Drug Metab
Toxicol. 5:1529–1542. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ding XW, Wu JH and Jiang CP: ABCG2: A
potential marker of stem cells and novel target in stem cell and
cancer therapy. Life Sci. 86:631–637. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bisson I and Prowse DM: WNT signaling
regulates self-renewal and differentiation of prostate cancer cells
with stem cell characteristics. Cell Res. 19:683–697. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sasaki N, Ishiwata T, Hasegawa F,
Michishita M, Kawai H, Matsuda Y, Arai T, Ishikawa N, Aida J,
Takubo K and Toyoda M: Stemness and anti-cancer drug resistance in
ATP-binding cassette subfamily G member 2 highly expressed
pancreatic cancer is induced in 3D culture conditions. Cancer Sci.
109:1135–1146. 2018. View Article : Google Scholar : PubMed/NCBI
|
